Carcinoid Syndrome

Endocrinology: Adult and Pediatric, Sixth Edition

Volumn 2, Issue , 2010, Pages 2774-2786

  Eriksson, Barbro ^a   Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85153810697     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5583-9.00153-2     Document Type: Chapter

References (135)

1. O Lubarsch (1867) Ueber den primaren Krebs des Ileum, nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberkuolose. Virchow Arch Pathol Anat Physiol Klin Med 111 280-317.
2. W Ransom (1890) A case of primary carcinoma of the ileum. Lancet 2 1020-1023.
3. S Oberndorfer (1907) Karzenoide Tumoren des Dünndarms. Frankf Zschr Pathol 1 426-430.
4. A Gosset and P Masson (1914) Tumeurs endocrines de l’appendice. Presse Med 25 237-239.
5. F Lembeck (1943) 5-Hydroxytryptamine in carcinoid tumor. Nature 172 910-911.
6. A Thorson, G Biorck, G Bjorkman, et al. (1954) Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis: A clinical and pathologic syndrome. Am Heart J 47 795-817.
7. ED Williams and M Sandler (1963) The classification of carcinoid tumours. Lancet 1 238-239.
8. I Norheim, E Theodorsson-Norheim, E Brodin, et al. (1986) Tachykinins in carcinoid tumors: Their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 63 605-612.
9. IM Modlin, KD Lye and M Kidd (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 934-959.
10. K Hemminki and X Li (2001) Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 92 2204-2210.
11. T Berge and F Linell (1976) Carcinoid tumours: Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand [A] 84 322-330.
12. E Wilander, M Lundqvist and K Oberg (1989) Gastrointestinal carcinoid tumours: Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects. Prog Histochem Cytochem 19 1-88.
13. G Kloppel, PU Heitz, C Capella, et al. (1996) Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 20 132-141.
14. C Solcia, C Capella, R Buffa, et al. (1981) Endocrine cells of the digestive system. L Johnson,(Eds) Physiology of the Gastrointestinal Tract New York: Raven Press 39-58.
15. M Brittan and NA Wright (2004) Stem cell in gastrointestinal structure and neoplastic development. Gut 53 899-910.
16. B Wiedenmann (1999) New molecular aspects for the clinical control of hypersecretion and proliferation in neuroendocrine tumor disease. M Mignon, JF Colombel,(Eds) Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors Montrouge: John Libbey 280-282.
17. B Wiedenmann, M John, G Ahnert-Hilger, et al. (1998) Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. J Mol Med 76 637-647.
18. E Solcia, R Fiocca, G Rindi, et al. (1993) The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 22 795-821.
19. G Qvigstad, T Qvigstad, B Westre, et al. (1992) Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS 110 132-139.
20. C Larsson, B Skogseid, K Oberg, et al. (1987) Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332 85-87.
21. F Latif, K Tory, J Gnarra, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 1317-1320.
22. AM Jakobsen, P Andersson, G Saglik, et al. (2001) Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. J Pathol 195 463-472.
23. E Solcia, G Kloppel and L Sobin (2000) Histological typing of endocrine tumours. New York: Springer pp 38–74 In (eds)
24. G Rindi, G Kloppel, H Alhman, et al. (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449 395-401.
25. J Zhao, RR de Krijger, D Meier, et al. (2000) Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. Am J Pathol 157 1431-1438.
26. D Granberg, E Wilander, K Oberg, et al. (2000) Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 85 3425-3430.
27. S Kytola, A Hoog, B Nord, et al. (2001) Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 158 1803-1808.
28. T Shimizu, S Tanaka, K Haruma, et al. (2000) Growth characteristics of rectal carcinoid tumors. Oncology 59 229-237.
29. N Sturm, G Rossi, S Lantuejoul, et al. (2002) Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 33 175-182.
30. M Kidd, IM Modlin, SM Mane, et al. (2006) The role of genetic markers—NAP1L1, MAGE-D2, and MTA1—in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol 13 253-262.
31. AM Oliveira, HD Tazelaar, KA Wentzlaff, et al. (2001) Familial pulmonary carcinoid tumors. Cancer 91 2104-2109.
32. JM Feldman and TM O'Dorisio (1986) Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 81 41-48.
33. RA Smith (1969) Bronchial carcinoid tumours. Thorax 24 43-50.
34. JM Feldman (1987) Carcinoid tumors and syndrome. Semin Oncol 14 237-246.
35. EM Tiensuu Janson and KE Oberg (1996) Carcinoid tumours. Baillieres Clin Gastroenterol 10 589-601.
36. W Creutzfeldt and F Stockmann (1987) Carcinoids and carcinoid syndrome. Am J Med 82 4-16.
37. WB Bean, D Olch and HB Weinberg (1955) The syndrome of carcinoid and acquired valve lesions of the right side of the heart. Circulation 12 1-6.
38. R Levin, L Elsas, C Duvall, et al. (1963) Malignant carcinoid tumors with and without flushing. JAMA 186 905-907.
39. RR Freedman, S Woodward and SC Sabharwal (1990) Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 76 573-578.
40. RR Freedman, D Norton, S Woodward, et al. (1995) Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 80 2354-2358.
41. Wyon Y: Vasomotor symptoms in postmenopausal women, Linköping Thesis, Linköping University, 2002.
42. DJ Demis (1963) The mastocytosis syndrome: Clinical and biological studies. Ann Intern Med 59 194-206.
43. C Parker, P Cryer and J Kissane (1976) Systemic mastocytosis. Am J Med 61 671-680.
44. LJ Roberts 2nd, BJ Sweetman, RA Lewis, et al. (1980) Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 303 1400-1404.
45. C Matuchansky and JM Launay (1995) Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites. Gastroenterology 108 743-751.
46. PC Emson, RF Gilbert, H Martensson, et al. (1984) Elevated concentrations of substance P and 5-HT in plasma in patients with carcinoid tumors. Cancer 54 715-718.
47. OB Schaffalitzky De Muckadell, S Aggestrup and P Stentoft (1986) Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man. Scand J Gastroenterol 21 498-502.
48. JI Robertson, WS Peart and TM Andrews (1962) The mechanism of facial flushes in the carcinoid syndrome. Q J Med 31 103-123.
49. JC Frolich, ZT Bloomgarden, JA Oates, et al. (1978) The carcinoid flush: Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 299 1055-1057.
50. R Furschgott and JU Zawadski (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 373-376.
51. RT Jensen (1999) Overview of chronic diarrhea caused by functional neuroendocrine neoplasms. Semin Gastrointest Dis 10 156-172.
52. M Donowitz and HJ Binder (1975) Jejunal fluid and electrolyte secretion in carcinoid syndrome. Am J Dig Dis 20 1115-1122.
53. J Debonguie and S Philips (1978) Capacity of the human colon to absorb fluid. Gastroenterology 74 698-703.
54. MR von der Ohe, M Camilleri, LK Kvols, et al. (1973) Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 329 1073-1078.
55. L Lundin, I Norheim, J Landelius, et al. (1988) Carcinoid heart disease: Relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 77 264-269.
56. WC Roberts and A Sjoerdsma (1964) The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease). Am J Med 36 5-34.
57. VJ Ferrans and WC Roberts (1976) The carcinoid endocardial plaque: An ultrastructural study. Hum Pathol 7 387-409.
58. L Lundin, J Landelius, B Andren, et al. (1990) Transoesophageal echocardiography improves the diagnostic value of cardiac ultrasound in patients with carcinoid heart disease. Br Heart J 64 190-194.
59. PA Robiolio, VH Rigolin, JS Wilson, et al. (1995) Carcinoid heart disease: Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92 790-795.
60. BI Gustafsson, K Tommeras, I Nordrum, et al. (2005) Long-term serotonin administration induces heart valve disease in rats. Circulation 111 1517-1522.
61. J Waltenberger, L Lundin, K Oberg, et al. (1993) Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 142 71-78.
62. B Jian, J Xu, J Connolly, et al. (2002) Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 161 2111-2121.
63. X Hua, JM Lundberg, E Theodorsson-Norheim, et al. (1984) Comparison of cardiovascular and bronchoconstrictor effects of substance P, substance K and other tachykinins. Naunyn Schmiedebergs Arch Pharmacol 328 196-201.
64. B Gardner, M Dollinger, W Silen, et al. (1967) Studies of the carcinoid syndrome: Its relationship to serotonin, bradykinin, and histamine. Surgery 61 846-852.
65. AI Vinik, MK McLeod, LM Fig, et al. (1989) Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 18 865-896.
66. L Andaker, LO Lamke and S Smeds (1985) Follow-up of 102 patients operated on for gastrointestinal carcinoid. Acta Chir Scand 151 469-473.
67. M Stridsberg, K Oberg, Q Li, et al. (1995) Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144 49-59.
68. FR Nobels, DJ Kwekkeboom, W Coopmans, et al. (1997) Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82 2622-2628.
69. K Oberg and M Stridsberg (2000) Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol 482 329-337.
70. M Grossmann, ME Trautmann, S Poertl, et al. (1994) Alpha-subunit and human chorionic gonadotropin-beta immunoreactivity in patients with malignant endocrine gastroenteropancreatic tumours. Eur J Clin Invest 24 131-136.
71. K Oberg, L Grimelius, G Lundqvist, et al. (1981) Update on pancreatic polypeptide as a specific marker for endocrine tumours of the pancreas and gut. Acta Med Scand 210 145-152.
72. B Eriksson, K Oberg and M Stridsberg (2000) Tumor markers in neuroendocrine tumors. Digestion 62(Suppl 1)), 33-38.
73. S Mani, IM Modlin, G Ballantyne, et al. (1994) Carcinoids of the rectum. J Am Coll Surg 179 231-248.
74. L Kolby, P Bernhardt, C Sward, et al. (2004) Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 120 269-273.
75. E Baudin, A Gigliotti, M Ducreux, et al. (1998) Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78 1102-1107.
76. WG Meijer, IP Kema, M Volmer, et al. (2000) Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 46 1588-1596.
77. AG Rockall and RH Reznek (2007) Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 21 43-68.
78. J Ricke, KJ Klose, M Mignon, et al. (2001) Standardisation of imaging in neuroendocrine tumours: Results of a European Delphi process. Eur J Radiol 37 8-17.
79. D Kwekkeboom, EP Krenning and M de Jong (2000) Peptide receptor imaging and therapy. J Nucl Med 41 1704-1713.
80. E Bombardieri, M Maccauro, E De Deckere, et al. (2001) Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 12(Suppl 2), S51-S61.
81. EP Krenning, M de Jong, PP Kooij, et al. (1999) Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10(Suppl 2), S23-S29.
82. H Orlefors, A Sundin, U Garske, et al. (2005) Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90 3392-3400.
83. JJ Erasmus, HP McAdams, EF Patz Jr, et al. (1998) Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 170 1369-1373.
84. G Kaltsas, M Korbonits, E Heintz, et al. (2001) Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86 895-902.
85. P Hellman, T Lundstrom, U Ohrvall, et al. (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26 991-997.
86. G Akerstrom and P Hellman (2007) Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21 87-109.
87. BK Eriksson, EG Larsson, BM Skogseid, et al. (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 2293-2301.
88. P Ruszniewski and D Malka (2000) Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 62(Suppl 1), 79-83.
89. E Berber, N Flesher and AE Siperstein (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26 985-990.
90. J Pless, W Bauer, U Briner, et al. (1986) Chemistry and pharmacology of SMS 201-995: a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl 119 54-64.
91. RT Jensen (1997) Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists. J Lewis, A Dubois,(Eds) Current Clinical Topics in Gastrointestinal Pharmacology Malden, MA: Blackwell Science 144.
92. B Eriksson and K Oberg (1999) Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook. Ann Oncol 10(Suppl 2)), S31-S38.
93. K Oberg (1998) Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 10 58-65.
94. P Ruszniewski, M Ducreux, JA Chayvialle, et al. (1996) Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39 279-283.
95. J Rubin, J Ajani, W Schirmer, et al. (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17 600-606.
96. P Tomassetti, M Migliori and L Gullo (1998) Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 93 1468-1471.
97. M Frank, KJ Klose, M Wied, et al. (1999) Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94 1381-1387.
98. B Eriksson, J Renstrup, H Imam, et al. (1997) High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol 8 1041-1044.
99. PM Stewart, SE Stewart, PM Clark, et al. (1999) Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf) 50 295-299.
100. YC Patel (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20 157-198.
101. JC Reubi, LK Kvols, B Waser, et al. (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50 5969-5977.
102. JC Reubi (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24 389-427.
103. C Susini and L Buscail (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17 1733-1742.
104. EP Krenning, DJ Kwekkeboom, WH Bakker, et al. (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20 716-731.
105. ET Janson, JE Westlin, B Eriksson, et al. (1994) [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Eur J Endocrinol 131 577-581.
106. AG Harris and JS Redfern (1995) Octreotide treatment of carcinoid syndrome: Analysis of published dose-titration data. Aliment Pharmacol Ther 9 387-394.
107. LK Kvols, JK Martin, HM Marsh, et al. (1985) Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 313 1229-1230.
108. K Oberg, G Lundqvist, et al. (1986) Treatment of the carcinoid syndrome with SMS 201-995, a somatostatin analogue. Scand J Gastroenterol 119 191-192.
109. PI-SS Ruszniewski, M Wymenga, et al. (2004) Rapid and sustained relief from the symptoms of carcinoma syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80 244-251.
110. L Kvols, K Oberg, E Glusman, et al. (2006) Safety and efficacy of pasireotide (SOM230) in patients with carcinoid syndrome refractory or resistant to octreotide LAR. J Clin Oncol 24(18S), 4082. ASCO Annual Meeting Proceedings. Part 1 Results of a phase II study
111. MC Trendle, CG Moertel and LK Kvols (1997) Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 79 830-834.
112. K Oberg, K Funa and G Alm (1983) Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 309 129-133.
113. K Oberg and B Eriksson (1991) The role of interferons in the management of carcinoid tumors. Acta Oncol 30 519-522.
114. Y Zhou, S Wang, A Gobl, et al. (2000) The interferon-alpha regulation of interferon regulatory factor 1 (IRF-1) and IRF-2 has therapeutic implications in carcinoid tumors. Ann Oncol 11 707-714.
115. CG Moertel, J Rubin and LK Kvols (1989) Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7 865-868.
116. LE Hanssen, E Schrumpf, AN Kolbenstvedt, et al. (1989) Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 24 787-795.
117. C Doberauer, B Mengelkoch, O Kloke, et al. (1991) Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha. Acta Oncologica 30(5), 603-605.
118. M Valimaki, H Jarvinen, P Salmela, et al. (1991) Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 67 547-549.
119. M Jakobsen, LE Hansen, F Kolmannskog, et al. (1995) Interferon-alfa 2b, with or without prior hepatic artery embolization: clinical response and survival in midgut carcinoid patients. Scand J Gastroenterol 30 789-796.
120. E Bajetta, N Zilembo, M Di Bartolomeo, et al. (1993) Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian Trials in Medical Oncology Group. Cancer 72 3099-3105.
121. U Plockinger and B Wiedenmann (2007) Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 21 145-162.
122. EM Tiensuu Janson, H Ahlstrom, T Anderson, et al. (1992) Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28A 1647-1650.
123. ET Janson and K Oberg (1993) Long-term management of the carcinoid syndrome: Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32 225-229.
124. J Zhang, Z Jia, Q Li, et al. (2007) Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109 1478-1486.
125. MH Kulke, HJ Lenz, NJ Meropol, et al. (2005) A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). J Clin Oncol 23(16s), 310s.
126. JC Yao, C Ng, PM Hoff, et al. (2005) Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 23(16S), 309s.
127. JC Yao, AT Phan, DZ Chang, et al. (2006) Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 24(18S), 189s. 2006 ASCO Annual Meeting Proceedings
128. CG Moertel (1983) Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1 727-740.
129. KL Melmon, A Sjoerdsma, JA Oates, et al. (1965) Treatment of malabsorption and diarrhea of the carcinoid syndrome with methysergide. Gastroenterology 48 18-24.
130. FQ Vroom, RE Brown, H Dempsey, et al. (1962) Studies on several possible antiserotonin compounds in a patient with the functioning carcinoid syndrome. Ann Intern Med 56 941-945.
131. H Schworer, H Munke, F Stockmann, et al. (1995) Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine. Am J Gastroenterol 90 645-648.
132. LJ Roberts 2nd, SR Marney Jr and JA Oates (1979) Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists: evidence for an important role of H2 receptors in human vasculature. N Engl J Med 300 236-238.
133. JR Buscombe, ME Caplin and AJ Hilson (2003) Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 44 1-6.
134. DJ Kwekkeboom, WH Bakker, PP Kooij, et al. (2001) [177Lu-DOTAOTyr3]octreotate: Comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 28 1319-1325.
135. DJ Kwekkeboom, WW de Herder, BL Kam, et al. (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 2124-2130.